Johnson & Johnson’s Daratumumab Gains Reimbursement Approval in Italy for First-Line Multiple Myeloma Treatment
Johnson & Johnson’s daratumumab has received reimbursement approval in Italy for the treatment of multiple myeloma in first-line therapy.